Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE

Inflammatory Bowel Diseases

Volumn 18, Issue 1, 2012, Pages 1-9

  Löfberg, Robert ^a   Louis, Edouard V ^b   Reinisch, Walter ^c   Robinson, Anne M ^d   Kron, Martina ^e   Camez, Anne ^e   Pollack, Paul F ^d  

^a Sophiahemmet AB   (Sweden)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ABBOTT LABORATORIES   (United States)

^e ABBOTT GMBH AND CO KG   (Germany)

Author keywords

adalimumab; Crohn's disease; extraintestinal manifestations; remission

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE;

ABDOMINAL ABSCESS; ADULT; ANKYLOSING SPONDYLITIS; APHTHOUS ULCER; ARTHRALGIA; ARTHRITIS; ARTICLE; BASAL CELL CARCINOMA; BLURRED VISION; BRONCHIECTASIS; BRONCHITIS; BRONCHOPNEUMONIA; CAMPYLOBACTERIOSIS; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM INFECTION; COHORT ANALYSIS; COLON FISTULA; CONDYLOMA ACUMINATUM; CONGESTIVE HEART FAILURE; CORTICOSTEROID THERAPY; CROHN DISEASE; DEMYELINATING DISEASE; DIVERTICULITIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; ENTEROCOLITIS; EPSTEIN BARR VIRUS INFECTION; ERYTHEMA NODOSUM; ESOPHAGUS CANDIDIASIS; EUROPE; EXTRAINTESTINAL MANIFESTATION; FEMALE; FOLLICULITIS; GASTROENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INTESTINE INFECTION; IRITIS; KLEBSIELLA INFECTION; LIVER DISEASE; LOADING DRUG DOSE; LUPUS LIKE SYNDROME; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MULTICENTER STUDY; NEPHROLITHIASIS; OPEN STUDY; OPPORTUNISTIC INFECTION; OROPHARYNX CANDIDIASIS; PELVIS ABSCESS; PERIANAL ABSCESS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PHYSICAL DISEASE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; PYELONEPHRITIS; PYODERMA GANGRENOSUM; REMISSION; SACROILIITIS; SEPSIS; SMALL INTESTINE CARCINOMA; THRUSH; THYROID FOLLICULAR CARCINOMA; TREATMENT RESPONSE; TUBERCULOSIS; URINARY TRACT INFECTION; UVEITIS; VAGINITIS; VIRAL GASTROENTERITIS; WOUND HEALING;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; CROHN DISEASE; FEMALE; HUMANS; INFECTION; MALE; MIDDLE AGED; NEOPLASMS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 83555163744     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21663     Document Type: Article

References (27)

1. Isaacs K,. Extra-intestinal manifestations. In:, Bayless T, Hanauer S, eds. Advanced Therapy of Inflammatory Bowel Disease. Hamilton, Ontario: BC Decker; 2001: 267-270.
2. Larsen S, Bendtzen K, Nielsen OH,. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med. 2010; 42: 97-114.
3. Sands BE,. Crohn's disease. Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 8th ed. Philadelphia: Saunders; 2006: 2459-2490.
4. Zold E, Nagy A, Devenyi K, et al. Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: two birds with one stone. World J Gastroenterol. 2009; 15: 2293-2295.
5. Podolsky DK,. Inflammatory bowel disease. N Engl J Med. 2002; 347: 417-429. (Pubitemid 34851835)
6. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323-333.
7. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146: 829-838. (Pubitemid 351650483)
8. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65. (Pubitemid 46108762)
9. Harvey RF, Bradshaw JM,. A simple index of Crohn's disease activity. Lancet. 1980; 315: 514.
10. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228-238. (Pubitemid 47080387)
11. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease. N Engl J Med. 1997; 337: 1029-1035.
12. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549. (Pubitemid 34621118)
13. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-250. (Pubitemid 47080388)
14. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-1239. (Pubitemid 47300424)
15. Nestorov I,. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol. 2005; 74: 13-18. (Pubitemid 40365775)
16. Schreiber S, Reinisch W, Colombel J, et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology. 2007; 132: A-147.
17. Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004; 63: 1664-16649.
18. Kaufman I, Caspi D, Yeshurun D, et al. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int. 2005; 25: 406-410. (Pubitemid 41186906)
19. Konrad A, Seibold F,. Response of cutaneous Crohn's disease to infliximab and methotrexate. Dig Liver Dis. 2003; 35: 351-356. (Pubitemid 41110863)
20. Kugathasan S, Miranda A, Nocton J, et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr. 2003; 37: 150-154. (Pubitemid 39274541)
21. Brooklyn T, Dunnill G, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006; 55: 505-509.
22. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009; 137: 1628-1640.
23. Juillerat P, Mottet C, Pittet V, et al. Extraintestinal manifestations of Crohn's disease. Digestion. 2007; 76: 141-148. (Pubitemid 351194909)
24. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8: 244-250. (Pubitemid 34784976)
25. Kugathasan S, Saubermann LJ, Smith L, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut. 2007; 56: 1696-1705. (Pubitemid 350206296)
26. Veny M, Esteller M, Ricart E, et al. Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients. Aliment Pharmacol Ther. 2010; 31: 561-572.
27. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1308-1319.